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ORIGINAL ARTICLE

CLINICO-PATHOLOGICAL PROFILE AND OUTCOMES OF PATIENTS
WITH POLYCYTHAEMIA VERA, ESSENTIAL THROMBOCYTHAEMIA
AND IDIOPATHIC MYELOFIBROSIS: A TERTIARY CARE CENTER
EXPERIENCE FROM SOUTHERN PAKISTAN
Muhammad Shariq Shaikh, Mohammad Usman Shaikh, Salman Naseem Adil,
Mohammad Khurshid*, Zeeshan Ansar Ahmed
Department of Pathology and Laboratory Medicine, *Department of Oncology, The Aga Khan University Hospital, Karachi-Pakistan

Background: The “Philadelphia Negative Classic Myeloproliferative Neoplasms” include
polycythaemia vera (PV), essential thrombocythaemia (ET) and idiopathic myelofibrosis (IMF).
These three disorders share several clinical and laboratory features including JAK2 V617F
mutation. Our objectives were to determine the clinico-pathological profile and outcomes of
Pakistani patients with polycythaemia vera (PV), essential thrombocythaemia (ET) and idiopathic
myelofibrosis (IMF) in order to have an insight regarding behaviour of these conditions.
Methods: A retrospective analysis of all the cases of PV, ET and IMF diagnosed at our institute
from January 1995 to December 2013 was performed. Age, gender, clinical presentation,
laboratory investigations, treatment provided and duration of follow-up were included for analysis.
Appropriate statistics were utilized for calculation of data. Results: A total of 58 patients were
diagnosed as PV, ET or IMF during the study period. Male to female ratio was 1.1:1. Forty five
percent (n=27) patients came to medical attention due to abnormal laboratory results, 3 had
cerebrovascular events, 3 had pruritus, and 1 patient each with gangrene and Budd-Chiari
syndrome. Haemorrhage was not seen in any patient. Sixty percent (n=35) patients were treated
with phlebotomy, hydroxyurea and aspirin alone or in combination. None of the patients
transformed to myelofibrosis (MF) or myelodysplasia (MDS) during the mean (±SD) follow-up
period of 57.2±50 months. One patient with ET transformed to acute myeloid leukaemia 9 years
after the diagnosis. Conclusions: This study demonstrated a relatively more benign form of PV,
ET and IMF with lesser frequency of symptoms, good response to treatment and less likelihood of
transformation to MF, MDS or AML.
Keywords: Myeloproliferative neoplasms, Polycythaemia vera, Essential thrombocythaemia,
Idiopathic myelofibrosis, Pakistan
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INTRODUCTION
The Myeloproliferative Neoplasms (MPNs) are
clonal disorders of haematopoietic stem cells
characterized by overproduction of one or more
myeloid cell lineages. Conditions which are
considered myeloproliferative neoplasms under the
classification used by the World Health
Organization1 include chronic myelogenous
leukaemia (CML), polycythaemia vera (PV),
essential thrombocythaemia (ET), idiopathic
myelofibrosis
(IMF),
chronic
neutrophilic
leukaemia (CNL), chronic eosinophilic leukaemianot otherwise specified (CEL-NOS), mastocytosis,
and myeloproliferative neoplasms unclassifiable
(MPN-U). Located in Philadelphia chromosome
(Ph), BCR-ABL1 gene is found positive only in
CML.
The three classic Ph-negative MPNs (PV,
ET and IMF) share several clinico-pathological
features. All three are characterized by marrow
hyper cellularity, risk of thrombosis, haemorrhage

and leukemic transformation. JAK2 V617F
mutation is another feature which is shared by
these three conditions. It is found positive in
approximately 95%, 60% and 50% cases of PV, ET
and IMF respectively. JAK2 V617F mutation is
often said to be associated with more aggressive
nature of these conditions. In PV and ET, it has
been found associated with higher haemoglobin2,3
and granulocyte levels,4,5 a greater incidence of
pruritus,2 a higher rate of fibrotic transformation2
and thrombosis6. Lower platelet counts and
increased risk of transformation to PV in JAK2
positive ET7,8 and more aggressive disease
phenotype with shortened overall survival have
been described with JAK2 positive IMF.
Patients with PV and ET come to medical
attention either due to abnormal laboratory results
or
may
have
symptoms
related
to
myeloproliferation like pruritus, thrombosis,
headaches, erythromelalgia, visual disturbances
and haemorrhage. Most patients with IMF on the
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contrary present with debilitating fatigue, anaemia,
early satiety secondary to marked splenomegaly
and constitutional symptoms. 9
Transformation into acute myeloid
leukaemia (AML), myelodysplastic syndrome
(MDS) and myelofibrosis (MF) are major causes
of death in PV.10 Median survival in PV if treated
is 10 years. Most patients with ET enjoy a normal
life expectancy without associated disease-related
complications 11 as evolution into either AML or
MF is unusual.12 Median survival in IMF
according to the series used for constructing the
International Prognostic Scoring System (IPSS)
was reported to be 69 months. 13
The goal of treatment in PV and ET is to
relieve symptoms and prevent thrombosis without
increasing the risk of bleeding. 14 Several
therapeutic modalities based on risk stratification
of these conditions have been described. 14 The
role
of
phlebotomy,
low-dose
aspirin,
hydroxyurea, interferon-alpha 15 and anagrelide is
well documented.
Literature search revealed lack of studies
from Pakistan addressing these three conditions.
Therefore, we aimed in determining clinicopathological profile and outcomes of patients
with PV, ET and IMF diagnosed at our centre.
This study will provide an insight to the
clinicians dealing with these three Philadelphianegative classic myeloproliferative neoplasms.

MATERIAL AND METHODS
This was a retrospective analysis performed in the
Section of Hematology, The Aga Khan University
Hospital. An exemption (2967-Pat-ERC-14) was
granted by institutional ethical review board for
conducting this study. All patients diagnosed as
PV, ET or IMF from January 1995 to December
2013 were included in the analysis. Medical
records were retrieved with the help of
institutional data management system.
The diagnosis of all three disorders was
made in accordance with the WHO criteria in use
at the time of first presentation (WHO criteria
2001 and 2008). Before that, diagnosis was made
based on Polycythaemia Vera Study Group
Criteria (PVSG).
Age, gender, clinical presentation,
laboratory investigations, treatment provided and
duration of follow-up were included for analysis.
Statistical package for social sciences (SPSS-19)
was utilized for data analysis (SPSS Inc.,
Chicago, IL, USA). Frequency and percentage
were calculated for categorical variables and
mean and standard deviation were computed for
quantitative variables.
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RESULTS
A total of 58 patients were diagnosed as PV, ET or IMF
during the study period. Male to female ratio was 1.1:1
with mean±SD age of 57.3±13.3 for males and
56.3±16.6 for females. The mean age and gender
distribution of study population with respect to the
diagnosis is shown in table-1.
For PV and ET, the most common reason for
consultation was abnormal complete blood count (CBC)
findings carried out as routine testing. Three of 6
patients with IMF presented with constitutional
symptoms. Two patients (1 male, 1 female) with PV and
one female with ET presented with stroke. None of the
patients with PV or ET had erythromelalgia or
haemorrhage. Other key presenting features and JAK2
V617F mutation status are detailed in table-1.
Haematological parameters of study population are
shown in table-2.
Thirty seven out of 58 patients (64%)
continued their follow-up in haematology outpatient
department. Of those who were treated, combination of
phlebotomy, hydroxyurea and aspirin was the most
common strategy for PV patients (Table 3). Twelve
patients who required therapeutic phlebotomies,
mean±SD haematocrit were 54.9±6.7 at the time of
diagnosis. The mean±SD units of whole blood (450ml
each approximately) taken out were 5.0±6.0 over the
mean±SD follow-up period of 77.8±59.5 months.
Interferon alpha and anagrelide were not utilized in any
patient. Most of the patients with ET received
hydroxyurea and aspirin in combination. None of the
patients with PV and ET transformed into MF or MDS
with a mean±SD follow-up period of 71.3±57.2 and
52±47 months respectively. Evolution into AML was
seen in one female patient with ET. She developed
AML 9 years after the initial diagnosis and subsequently
succumbed to this aggressive condition. All four
patients with IMF were treated differently (Table 3)
with only one patient requiring red cell transfusions.
Three patients with IMF (1 on no treatment, 1 on
hydroxyurea and 1 on aspirin only) remained stable with
a median follow-up of 32±18.7 months. Treatment
details and follow-up duration of study population are
shown in table-3.
JAK2 V617F mutation was found positive in
89.3%, 58.3% and 66.7% of patients with PV, ET and
IMF respectively (Table-1). Of 31 symptomatic
patients, 25 (81%) were positive for this mutation
including patients with cerebrovascular events, gangrene
and Budd-Chiari syndrome (Table 4). Similarly,
haematological parameters were higher in patients with
JAK2 V617F positive mutation status except for the
platelet count which was low (Table-4). Single patient
with ET who transformed to AML was negative for this
mutation.
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Table-1: Age, gender, clinical features and JAK2 V617F mutation status of study population
PV
ET
IMF
28 (48.3%)
24 (41.4%)
6 (10.3%)
Number of Patients (%)
Males
19 (67.8%)
5 (20.8%)
6 (100%)
Females
9 (32.2%)
19 (79.2%)
0
Age in years (Mean±SD)
Males
52.5±12.6
61.4±8.3
59.5±19.8
Females
64±14.8
53.6±15.9
Presenting symptoms
Constitutional symptoms (night sweats, weight loss, fever)
3 (10.7%)
0
3 (50%)
Abnormal laboratory findings
14 (50%)
13 (54.2%)
Symptoms influencing daily activities (fatigue, insomnia, inactivity)
4 (14.3%)
4 (16.6%)
1 (16.7%)
Complaints related to myeloproliferation (Bone pains, itching)
3 (10.7%)
5 (20.8%)
1 (16.7%)
Cerebrovascular event
2 (7.1%)
1(4.2%)
Gangrene
1 (3.6%)
Budd-Chiari
1 (3.6%)
Symptoms of splenomegaly
0
1(4.2%)
1 (16.7%)
8 (28.6%)
4 (66.7%)
Palpable Splenomegaly
JAK2 V617F Mutation(a)
Positive
25 (89.3%)
14 (58.3%)
4 (66.7%)
Negative
3 (10.7%)
10 (41.7%)
2 (33.3%)
(a) JAK-2 mutation analysis in 9 patients was performed during follow-up period when this test became available in 2008; all were positive

Table-2: Haematological parameters of study population
Diagnosis
PV
ET
IMF

Sex

Haemoglobin
(g/dl)
18.2±2.0
17.1±2.2
11.6±1.9
13±1.4
11.4±2

Male (n=19)
Female (n=9)
Male (n=5)
Female (n=19)
Male (n=6)

Haematocrit
(%)
56.4±6.2
54.3±6.7
37.7±6.1
39.8±4.5
34.6±7.0

RBC
(X 1012/L)
8.8±6.1
6.8±0.9
4.0±0.1
4.9±0.7
3.7±0.4

MCV
(fl)
75.1±17.0
81.1±13.1
83.6±3.4
84.8±8.5
74.1±14.3

MCH
(pg)
24.9±3.7
26.0±4.4
27.5±1.6
27.8±3.1
24.5±5.9

WBC
Platelets
(X 109/L) (X 109/L)
20.4±13
470±182
22±13.8
569±228
16.1±10.4 1375±781
11.5±3.7 968±442
20.3±17
636±623

Table-3: Treatment details and follow-up of patients who continued their treatment in our institution (n=37)
Treatment
Wait and Watch
Hydroxyurea
Aspirin
Phlebotomy + Hydroxyurea + Aspirin
Hydroxyurea + Aspirin
Hydroxyurea + RBC transfusions
In follow-up
Lost to follow
Mean follow-up (months)

PV
0
0
0
12 (85.7%)
2 (14.3%)
0
14 (50%)
14 (50%)
71.3±57.2

Table-4: Clinical features and haematological
parameters in patients with respect to JAK2(V617F) mutation status
Number of patients
Abnormal laboratory results
Constitutional symptoms
Symptoms of splenomegaly
Symptoms influencing daily
activities
Symptoms related to
myeloproliferation
Cerebrovascular events
Budd-Chiari Syndrome
Gangrene
Haemoglobin (g/dl)
Haematocrit (%)
Red Blood Cells (X 1012/L )
White blood cells (X 109/L)
Platelets (X 109/L)

JAK2 V617F
Positive
43 (74%)
18 (41.8%)
5 (11.6%)
1 (2.3%)
7 (16.3%)

JAK2 V617F
Negative
15 (26%)
9 (60%)
1 (6.7%)
1 (6.7%)
2 (13.3%)

8 (18.7%)

1 (6.7%)

2 (4.7%)
1 (2.3%)
1 (2.3%)
15.5±3.2
48.4±10.5
7.3±4.7
19.4±12.3
716±485

1 (6.7%)
0
0
13.3±3.0
41.5±8.8
4.8±0.6
10.1±2.9
876±535

ET
0
5 (26.3%)
2 (10.5%)
0
12 (63.2%)
0
19 (79%)
5 (21%)
52±47

IMF
1 (25%)
1 (25%)
1 (25%)
0
0
1 (25%)
4 (66.6%)
2 (33.3%)
32.0±18.7

DISCUSSION
Our study ascertained several important facts in
Pakistani patients with PV, ET and IMF. To the best
of our knowledge, it is the first study from Pakistan
detailing clinico-pathological profile of patients with
PV, ET and IMF. The median age at presentation for
all three conditions in our study is comparable to that
described in the literature (Table-1). Sex ratios for
PV, ET and IMF in this study are quite different from
international data. Male to Female ratio in PV was
2.1:1 which is almost double. Female preponderance
in ET (female to male ratio of 2:1) has been reported
in several studies however, female to male ratio was
found to be 3.8:1 in this study. All 6 patients with
IMF were males. Although PV and ET are identified
by chance in a proportion of patients, almost half of
the patients with these conditions in our study came
to medical attention due to incidental abnormal
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laboratory findings (Table-2). Only three (10.7%)
patients with PV had pruritus whereas, it has been
reported in as high as 68% of the patients with PV.16
Thrombotic events were present in four (14.3%)
patients with PV (cerebrovascular event in 2, BuddChiari syndrome in 1 and gangrene in 1). These
figures are comparable to international data.17 In ET
however, only one (4.2%) patient presented with
cerebrovascular thrombosis. Incidence rates of
thrombosis in ET varying from 9 to 22 percent have
been described in various studies.12,18
Patients who continued their follow-up in
our institute, hydroxyurea in combination with
aspirin was the most common treatment modality
utilized for PV and ET. Considering the follow-up
period of 77.8±59.5 months in patients with PV who
required phlebotomies, the requirement for it was low
(5.0±6.0 units of whole blood). Patient with both PV
and ET responded well to hydroxyurea with no
events of thrombosis, transformation or death (except
one patient). Higher risk of both disease
transformation and death in hydroxyurea resistance
disease has been published in literature.19,20 In
patients with MF, calculation of scores according to
Dynamic International Prognostic Scoring System21
(DIPSS) revealed following results: intermediate
risk-1 (5 patients) and intermediate risk-2 (1 patient).
One patient with intermediate risk-2 DIPSS score
remained clinico-haematologically stable during the
follow-up period of 20 months. Median survival in
intermediate risk-2 category according to DIPSS is 4
years.21
The prevalence of JAK2 V617F mutation in
this study is comparable to available international
literature (Table-1). The more aggressive clinicopathological features in JAK2 V617F mutation
positive patients as well as lower platelet counts are
in accordance with other reported studies.7,8
Interestingly, the single patient with ET who
developed AML after 9 years of initial diagnosis was
negative for this mutation.
Besides being the first study from Pakistan
detailing clinico-pathological features and outcomes
of patients with PV, ET and IMF, other strength of
this study is its long duration (19 years; from 1995–
2013) and reasonable follow-up (57.2±50 months).
Although the sample size is not large enough
however, considering the annual incidence of 0.5-2.5
cases per 100,000 populations in western countries,
the current data from a tertiary care centre provides a
passable insight into behaviour of these conditions in
study population. We could not provide the data on
frequency of other mutations like exon 12 mutation
in PV and MPL gene in ET due to unavailability of
these tests at our institute. Similarly, quantification of
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JAK2 V617F burden to assess risk of thrombosis
could not be scrutinized.

CONCLUSIONS
This study demonstrated a relatively more benign
form of PV, ET and IMF with lesser frequency of
symptoms and good response to treatment.
Transformation
to
aggressive
forms
like
myelofibrosis and myelodysplasia were also not seen
in any patient. The possible influence of genetic and
environmental factors on milder phenotype of these
conditions in Pakistani population needs further
exploration.
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